OS Therapies Inc — fact timeline

OS Therapies Inc entered into Purchase Agreement with purchasers identified on the signature pages thereto (effective 2026-03-31).

“On March 31, 2026, OS Therapies Incorporated (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers identified on the signature pages thereto (the “Purchasers”), pursuant to which the Company offered for sale to the Purchasers in a registered direct offering (the “Offering”) an aggregate of 2,505,073 shares of its common stock and, in lieu thereof, pre-funded warrants to purchase up to 1,250,893 shares of its common stock (the “pre-funded warrants”), and accompanying warrants to purchase up to 3,755,966 shares of its common stock (the “common warrants”).”

OS Therapies Inc incurred convertible notes of $2,200,000 at 4% per annum maturing March 4, 2027.

“Pursuant to the Purchase Agreement, the Company issued to the Purchasers (i) Notes in an aggregate principal amount of $2,200,000 and (ii) Warrants to purchase up to 1,666,667 shares of the Company’s common stock (the “Warrant Shares”), for aggregate gross proceeds of $2,000,000, before deducting placement agent fees and other Private Placement expenses.”

OS Therapies Inc entered into Purchase Agreement with certain accredited investors valued at $2,200,000 aggregate principal amount of Notes and $2,000,000 aggregate gross proceeds (effective 2026-03-04).

“On March 4, 2026, OS Therapies Incorporated (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors (collectively, the "Purchasers"), pursuant to which the Company agreed to issue and sell to the Purchasers, in a private placement (the "Private Placement"), (i) 10.0% original issue discount unsecured convertible promissory notes (the "Notes") and (ii) warrants to purchase shares of the Company's common stock (the "Warrants" and, together with the Notes, the "Securities").”

OS Therapies Inc entered into Inducement Letters with less than 10 accredited investors valued at approximately $7.5 million (effective 2026-01-10).

“On January 10, 2026, OS Therapies Incorporated (the “Company”) entered into inducement offer letter agreements (the “Inducement Letters”) with less than 10 accredited investors (the “Holders”)”

OS Therapies Inc: Amended Section 3.10 of Bylaws to change stockholder meeting quorum to one-third of voting power entitled to vote, present in person or by proxy (effective 2025-08-15).

“On August 15, 2025, the Board of Directors (the “Board”) of OS Therapies Incorporated (the “Company”) approved and adopted an amendment (the “Amendment”) to Section 3.10 of Article III of the Company’s Amended and Restated Bylaws (the “Bylaws”), effective as of such date, to change the quorum for the transaction of business at stockholder meetings to one-third of the voting power of the outstanding shares of stock of the Company entitled to vote on a matter at the meeting, present in person or represented by proxy.”

Karim Galzahr was elected as Director at OS Therapies Inc.

“On January 28, 2025, Karim Galzahr was elected to the Company’s board of directors.”

Olivier R. Jarry was appointed as director at OS Therapies Inc.

“Avril McKean Dieser and Olivier R. Jarry joined the Board, effective October 28, 2024.”

Avril McKean Dieser was appointed as director at OS Therapies Inc.

“Avril McKean Dieser and Olivier R. Jarry joined the Board, effective October 28, 2024.”

Joacim Borg resigned as director at OS Therapies Inc.

“Also, effective October 28, 2024, Joacim Borg notified the Board of his resignation as a director, effective immediately.”

Colin Goddard resigned as Chairman of the Board and director at OS Therapies Inc.

“Effective October 28, 2024, Colin Goddard, Ph.D. notified the Board of Directors (the “Board”) of the Company of his resignation as the Chairman of the Board and director of the Company, effective immediately.”